Sai Parenteral's Limited IPO – Complete Review, Financials & Analysis

Sai Parenteral's Limited IPO is one of the notable pharmaceutical sector public issues in 2026. The company operates in the injectable pharmaceutical segment and offers a mix of branded generics and contract development and manufacturing (CDMO) services, catering to both domestic and global markets.

The IPO is attracting attention due to its improving profitability, expanding margins, and growing demand for injectable medicines worldwide.

About Sai Parenteral's Limited

Sai Parenteral's Limited is a pharmaceutical company focused on manufacturing sterile injectable products. The company has a diversified product portfolio and serves hospitals, healthcare institutions, and international markets.

Its business model is divided into two main verticals:

• Branded generic formulations

• CDMO (Contract Development and Manufacturing)

The company benefits from strong manufacturing capabilities, regulatory approvals, and an expanding export footprint.

Sai Parenteral's IPO Details

Sai Parenteral's IPO is a mainboard issue and is expected to open in March 2026. The price band is reported in the range of ₹372 to ₹392 per share.

The total IPO size is around ₹408.79 crore, which includes a fresh issue and an offer for sale.

The funds raised from the IPO will be used for:

• Expansion of manufacturing facilities

• Setting up a new R&D center

• Debt repayment

• Working capital requirements

Financial Performance

Sai Parenteral's Limited has shown steady growth in revenue along with strong improvement in profitability.

For FY2025, the company reported:

• Revenue of around ₹163.10 crore

• EBITDA of approximately ₹40.01 crore

• Profit After Tax (PAT) of about ₹14.42 crore

The company has delivered consistent growth over the past few years:

• Revenue increased from ₹97 crore in FY2023 to ₹163 crore in FY2025

• PAT grew significantly from ₹4.38 crore to ₹14.45 crore during the same period

This reflects strong business expansion and improving operational efficiency.

Key Financial Ratios

Sai Parenteral's has shown improvement in key profitability and efficiency ratios:

• EBITDA margin stands at around 24.53%

• PAT margin is approximately 8.84%

• Return on Equity (ROE) is about 15.06%

• Return on Capital Employed (ROCE) is around 28.90%

• Debt-to-equity ratio has improved to 0.98

The steady increase in margins and reduction in debt indicates better financial stability and operational control.

Growth Trends

The company has shown:

• Revenue growth of over 6% in the latest year

• PAT growth of more than 70% year-on-year

• EBITDA growth of over 20%

Such growth reflects increasing demand, better cost management, and improved product mix.

Strengths of the Company

Sai Parenteral's Limited has several competitive advantages:

• Strong presence in injectable pharmaceutical segment

• Growing CDMO business with global opportunities

• Modern manufacturing facilities with regulatory approvals

• Increasing export market penetration

• Experienced management team

Risks to Consider

Despite strong growth, investors should consider certain risks:

• High competition in pharmaceutical manufacturing

• Dependence on regulatory approvals

• Moderate profit margins compared to industry leaders

• Exposure to raw material price fluctuations

Industry Outlook

The injectable pharmaceutical segment is growing rapidly due to:

• Increasing hospital demand

• Rise in chronic diseases

• Global outsourcing trends for manufacturing

India is becoming a major hub for pharmaceutical exports, which benefits companies like Sai Parenteral's.